Supporting Consumers Across the GLP-1 Journey

We are pleased to share a concise set of topline insights highlighting the rapidly growing opportunities for Consumer Health companies within the Cardiovascular/Renal/Metabolic (CVRMET) landscape.

As GLP-1 therapies continue to reshape obesity and cardiometabolic care, they also create new, sustained needs for patients and consumers, needs that extend well beyond the prescription itself. This shift opens significant space for food supplements, nutrition solutions, and consumer health innovations that can support individuals before, during, and after GLP-1 treatment as part of broader lifestyle change journeys.

Rather than focusing on the pharmaceutical therapy, these insights explore the complementary role Consumer Health can play across three key domains:

• Digestive and tolerance support (e.g., nausea, reflux, constipation management)
• Nutrition and muscle preservation (including protein density and micronutrient supplementation)
• Hydration, energy, and overall wellbeing (addressing fatigue, hydration gaps, and visible side effects)

Together, these areas form a GLP-1 support ecosystem with durable demand and strong relevance for Consumer Health portfolios.

Given the importance and momentum of this topic, we are sharing these insights selectively and directly with you via this link.

Join us at BACHI – 19 May

We will further explore the largest CVRMET related opportunities for Consumer Health during a dedicated BACHI session on 19 May. During this session, we will dive deeper into the implications of GLP-1 usage and the role Consumer Health companies can play in supporting long-term lifestyle and wellbeing goals.

We would be delighted if you could join us.

Let’s continue the conversation

Should you have any questions or wish to discuss the GLP-1 market evolution or broader Consumer Health implications, please feel free to reach out to your IQVIA Key Account Manager.